Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042561 · ClinicalTrials.gov registry record · NA
Vitamin D Status and Dose Response in Infants
A NA study, sponsored by University of Nebraska.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT01042561: Completed NA study, sponsored by University of Nebraska.
NCT01042561 is a NA study that has completed, run by University of Nebraska. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01042561, a NA study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study will examine the relationship of serum 25(OH)D levels in infants 32 weeks and greater gestation who are fed infant formula to markers of inflammation and bone metabolism.
Primary Outcome
Total serum 25(OH)D level is currently considered the best indicator of vitamin D supply to the body from cutaneous synthesis and nutritional intake. For infants, ≤37.5 nmol/L (15 ng/mL) would be considered indicative of deficiency and \>50 nmol/L (20 ng/mL) as indicative of vitamin D sufficiency.
Interventions
- DIETARY_SUPPLEMENT Vitamin D3
- DIETARY_SUPPLEMENT vitamin D3 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2009-08-07 |
| Est. Completion | 2010-08-01 |
| Phase | NA |
What the finished NCT01042561 record still lists
NCT01042561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Vitamin D3 is the first listed.
NCT01042561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01042561 about?
NCT01042561 is a clinical study titled "Vitamin D Status and Dose Response in Infants". This study will examine the relationship of serum 25(OH)D levels in infants 32 weeks and greater gestation who are fed infant formula to markers of inflammation and bone metabolism.
What is the current status of trial NCT01042561?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2009-08-07. Estimated completion is 2010-08-01.
What interventions are being tested in trial NCT01042561?
The interventions under investigation include: Vitamin D3 (DIETARY_SUPPLEMENT), vitamin D3 placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01042561?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01042561's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI